【2026 年 03 月】 融捷股份有限公司 2025 年度报告全文 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完整，不存在虚 假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人吕向阳、主管会计工作负责人冯志敏及会计机构负责人（会计主管人员） 冯志敏声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 年度报告涉及未来计划等前瞻性陈述，只是公司生产经营计划的预测，不构成公司 对投资者的实质性承诺，投资者及相关人士均应当对此保持足够的风险意识，并且应当理 解计划、预测与承诺之间的差异。 公司业务运营可能面临产业政策变化的风险、锂产品价格波动风险、委外选矿量对 公司经营成果影响的不确定性风险、少数客户及关联方依赖风险、锂矿外部环境和采选相 关安全环保风险、选矿扩能项目投产时间不确定性的风险等，详情请查阅"第三节 管理 层讨论与分析"之"十一、公司未来发展的展望"之"（四）面临的风险和应对措施"相 关内容，请投资者注意阅读相关风险并谨慎决策。 公司经本次董事会审议通过的利润分配预案为：以公司现有总股本 25 ...

光智科技股份有限公司 2025 年年度报告全文 光智科技股份有限公司 2025 年年度报告 2026-009 2026 年 3 月 1 光智科技股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律 责任。 公司负责人朱世彬、主管会计工作负责人蒋桂冬及会计机构负责人（会 计主管人员）王玮玮声明：保证本年度报告中财务报告的真实、准确、完 整。 所有董事均已出席了审议本报告的董事会会议。 有关公司本年度净利润为负值及改善盈利能力的相关措施已在本报告第 三节"管理层讨论与分析"部分予以描述。敬请广大投资者关注，注意投资 风险。 本报告如有涉及未来计划、发展战略等前瞻性陈述，均不构成公司对任 何投资者及相关人士的实质承诺，投资者及相关人士均应对此保持足够的风 险认识，并且应当理解计划、预测与承诺之间的差异。 本公司特别提醒投资者关注公司可能存在的下述风险：宏观经济波动风 险、汇率波动风险、原材料价格波动风险。详见本报告"第三节 管理层讨论 与分析"之" ...

Financial Performance - Total revenue for 2025 reached RMB 153,993.14 million, a 26.10% increase compared to RMB 122,119.00 million in the previous year[4] - Operating profit improved significantly to RMB 9,512.92 million, compared to a loss of RMB 13,954.94 million in the previous year, marking a 168.17% increase[4] - Net profit attributable to shareholders was RMB 8,525.78 million, a turnaround from a loss of RMB 15,046.57 million, representing a 156.66% increase[4] - The basic earnings per share rose to RMB 0.2630, compared to a loss of RMB 0.4588 per share in the previous year, reflecting a 157.32% improvement[4] - The weighted average return on equity increased to 6.21%, up from -10.06% in the previous year, indicating a 16.27% improvement[4] Assets and Equity - Total assets at the end of the reporting period were RMB 226,195.96 million, a 9.57% increase from RMB 206,435.34 million at the beginning of the period[4] - Shareholder equity rose to RMB 140,581.44 million, a 5.23% increase from RMB 133,599.68 million at the beginning of the period[4] Revenue Growth - The company achieved significant growth in overseas revenue, contributing to the overall revenue increase, driven by enhanced product value and solution capabilities[5] Cost Management - The company has optimized its cost control and resource allocation, leading to a decrease in the expense ratio compared to the previous year[5] Non-Recurring Items - Non-recurring gains and losses impacted net profit by RMB 1,079.97 million, primarily from government subsidies received[6]

Financial Projections - The estimated net profit for Q1 2026 is projected to be between RMB 38 million and RMB 48 million, representing a year-on-year growth of 79.23% to 126.40% compared to RMB 21.20 million in the same period last year[4] - The net profit after deducting non-recurring gains and losses is expected to be between RMB 36 million and RMB 46 million, indicating a year-on-year increase of 85.07% to 136.47% from RMB 19.45 million last year[4] - The impact of non-recurring gains and losses on net profit is estimated to be approximately RMB 2 million[6] Business Growth - The company has experienced significant growth in overseas market expansion, contributing to a rapid increase in overseas business revenue during the reporting period[6] - The company is focused on optimizing product structure and improving operational efficiency, which has enhanced overall profitability[6] Financial Reporting - The financial data presented is preliminary and has not yet been audited by the accounting firm[5] - The specific financial data will be disclosed in detail in the Q1 2026 report[8] - The company emphasizes compliance with legal regulations for timely information disclosure to investors[8] - The performance forecast period is from January 1, 2026, to March 31, 2026[3] - The board of directors has confirmed the accuracy and completeness of the information disclosed[2]

江苏日久光电股份有限公司 2025 年年度报告全文 江苏日久光电股份有限公司 2025 年年度报告 【2026 年 3 月】 1 江苏日久光电股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人陈超、主管会计工作负责人余寅萍及会计机构负责人（会计 主管人员）余寅萍声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告所涉及的发展战略及未来计划等前瞻性陈述，不构成公司对投资 者的实质性承诺。投资者及相关人士均应当对此保持足够的风险认识，并应 当理解计划、预测与承诺之间的差异，敬请广大投资者注意投资风险。 公司在本报告"第三节 管理层讨论与分析"之"公司未来发展的展望" 部分，详细描述了公司经营中可能面临的风险，敬请广大投资者关注相关内 容。 公司经本次董事会审议通过的利润分配预案为：以公司未来实施分配方 案时股权登记日的总股本扣减公司回购专用证券账户中股份总数为基数，向 全体股东 ...

国城矿业股份有限公司 2025 年年度报告全文 国城矿业股份有限公司 2025 年年度报告 2026 年 3 月 国城矿业股份有限公司 2025 年年度报告全文 2025 年年度报告 第一节 重要提示、目录和释义 公司董事会及董事、高级管理人员保证年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责 任。 公司负责人吴城、主管会计工作负责人姜静及会计机构负责人（会计主 管人员）高端声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司在本报告第三节"管理层讨论与分析"的"十一、公司未来发展的展望" 部分描述了可能面对的相关风险和应对措施，敬请投资者注意查阅。 公司经本次董事会审议通过的利润分配预案为：以 1,185,067,706 为基数， 向全体股东每 10 股派发现金红利 1.30 元（含税），送红股 0 股（含税），不 以公积金转增股本。 1 | 第一节 | 重要提示、目录和释义 1 | | --- | --- | | 第二节 | 公司简介和主要财务指标 6 | | 第三节 | 管理层讨论与分析 11 | | 第四 ...

Financial Performance Expectations - The company expects to achieve an operating revenue of approximately CNY 315 million for 2025, with a net profit attributable to shareholders of about CNY 4.5 million, and a non-recurring net profit of approximately -CNY 7 million, representing a year-on-year decrease of about CNY 12.81 million or 220%[2] - The decline in performance is primarily attributed to a decrease in revenue from the health products segment for 2025[2] - The company expects a net profit attributable to shareholders of approximately 4.50 million for 2025, with a non-recurring net profit of approximately -7.00 million[30] - The estimated non-recurring profit and loss for 2025 is approximately 1,150 million[31] Revenue Breakdown by Segment - The health products segment generated revenue of CNY 136.68 million, while the medical and nursing segment contributed CNY 157.84 million, and the real estate segment accounted for CNY 16.81 million, totaling CNY 314.70 million across all segments[6] - The total revenue for the health product segment is CNY 13,667.94 million, with online sales contributing CNY 3,459.95 million and offline sales contributing CNY 10,207.99 million[19] - The real estate segment's total revenue from leasing activities reached CNY 111.44 million, with the largest lease contributing CNY 26.27 million[12] - The company reported a total of CNY 28.00 million in revenue from pawn services in the other segment, with the largest transaction amounting to CNY 4.23 million[14] Customer and Supplier Relationships - The top ten customers in the health products segment accounted for a total sales revenue of CNY 704.02 million, with the largest customer contributing CNY 172.82 million[7] - The total procurement amount from major suppliers in the health product segment is CNY 18,072,295.36, with long-term cooperation established for over 10 years with several suppliers[16] - The total procurement amount from major suppliers in the medical care segment is CNY 29,225,386.59, with ongoing relationships since 2019 for most suppliers[16] - The company confirmed that there are no related party transactions between major customers and suppliers, ensuring compliance with regulations[17] Revenue Recognition and Compliance - The company is required to disclose detailed information regarding revenue recognition, customer transactions, and sales return situations for 2025[2] - The revenue recognition policy adheres to the new revenue standards, with all sales confirmed based on external evidence such as customer acceptance and logistics records[23] - The company has established clear revenue recognition policies for each business segment, ensuring compliance and accuracy in financial reporting[22] - The company’s revenue recognition practices are in line with the five-step model of the new revenue standards, ensuring that all criteria are met before recognizing revenue[22] Financial Management and Liabilities - As of the end of 2025, the company's cash and cash equivalents decreased to 263.12 million yuan from 481.99 million yuan, while total assets decreased to 45.38 million yuan from 53.53 million yuan[34] - The company’s total liabilities decreased to 17.54 million yuan from 29.07 million yuan, with other payables decreasing to 17.47 million yuan from 28.99 million yuan[34] - The company’s total equity increased to 27.84 million yuan from 24.46 million yuan, with retained earnings showing a slight improvement[34] - The company reported a decrease in other receivables by 6.4 million yuan due to the recovery of loans from related parties[35] Audit and Compliance Measures - The total revenue for the auditing firm for 2025 is projected to be 8,829,077.84 yuan, with the audit fee for the company being 1.2 million yuan, representing approximately 13.59% of the firm's total revenue[63] - Shenzhen Zhengyi has implemented specific measures to maintain independence, including prohibiting direct economic relationships with clients outside of professional service fees[66] - The company has established a quality control review system, categorizing the annual report audit as Class A business and implementing a seven-level review process[66] - The audit team will maintain independence and reasonable professional skepticism, adhering strictly to accounting and auditing standards[68] Legal and Litigation Matters - The ongoing litigation involving Angli Small Loan may have uncertain impacts on the company's financial reports, as the outcome is still pending[38] - The company successfully defended against a lawsuit regarding a 40 million yuan fund transfer, with the court ruling in favor of Jiuding Pawn[51] - The debt relationship between Jiuding Pawn and the company was confirmed in 2024, following a court ruling that resolved uncertainties regarding a lawsuit involving a minority shareholder[57] Loan Management and Provisions - Jiuding Pawn's financial management includes a provision policy that mandates a 50%-75% provision for doubtful loans, ensuring prudent risk management[53] - The company reported a total of 5.7 million yuan in loans to Angli Small Loan, with a significant portion classified as impaired[52] - Jiuding Pawn classified the remaining 1.25 million yuan loan from Angli Small Loan as "doubtful" and provisioned for 937.5 thousand yuan, reflecting a 75% impairment rate[53] - The company plans to return 4.5 million yuan to Jiuding Pawn in 2025, which will lead to a reversal of the corresponding impairment provision[59]

北京四方继保自动化股份有限公司2025 年年度报告 公司代码：601126 公司简称：四方股份 北京四方继保自动化股份有限公司 2025 年年度报告 2 / 221 北京四方继保自动化股份有限公司2025 年年度报告 重要提示 一、本公司董事会及董事、高级管理人员保证年度报告内容的真实性、准确性、完整性，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、公司全体董事出席董事会会议。 三、 中证天通会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、公司负责人高秀环、主管会计工作负责人付饶及会计机构负责人（会计主管人员）周阳声明：保 证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 根据中证天通会计师事务所（特殊普通合伙）审计，截至 2025 年 12 月 31 日，公司母公司累计可 供股东分配的利润为 954,778,076.16 元。公司拟以 2025 年末总股本 833,183,500 股为基数，每 10 股派 发现金 7.2 元（含税），合计拟派发现金红利 599,892,120 元（含税）。剩余未分配 ...

Financial Performance - The company expects a net profit of between 52 million and 75 million yuan for Q1 2026, representing a year-on-year increase of 2222.67% to 3250.01% compared to 2.24 million yuan in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is projected to be between 50 million and 73 million yuan, a significant improvement from a loss of 22.60 million yuan in the previous year[3]. - The financial data in the earnings forecast has not been audited by an accounting firm, and the specific financial data for Q1 2026 will be disclosed in the company's quarterly report[4][7]. Industry Growth - The growth in performance is attributed to the continuous improvement in the new energy industry, with stable demand for power batteries and rapid growth in the energy storage battery market, driving the demand for upstream lithium battery materials[5]. Strategic Plans - The company plans to consolidate its market advantage in the pharmaceutical sector while expanding capacity and ensuring supply in the new energy sector through technological upgrades[6]. - The synthetic biology segment has made significant progress, with the company's protein product being included in the first batch of "biomanufacturing landmark products" by the Ministry of Industry and Information Technology[6]. - The company aims to accelerate the construction and capacity release of its microbial protein project, expanding application scenarios and entering domestic and international markets[6].

Financial Projections - The total operating revenue for 2025 is estimated at 1,184.99 million yuan, a year-on-year increase of 0.61%[5] - Operating profit is projected at -61.55 million yuan, showing an improvement of 78.56% compared to the previous year[5] - The total profit is expected to be -63.14 million yuan, reflecting a 78.12% increase from the prior year[5] - The net profit attributable to shareholders is forecasted at -53.07 million yuan, an improvement of 80.50% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses is estimated at -81.06 million yuan, a 73.38% improvement compared to last year[5] - Basic earnings per share are projected at -0.10 yuan, an increase of 80.39% from -0.51 yuan in the previous year[5] - The weighted average return on net assets is expected to be -2.43%, improving by 9.19% from -11.62%[4] Asset and Equity Overview - Total assets at the end of the reporting period are estimated at 4,407.99 million yuan, a decrease of 2.84% from the beginning of the period[4] - The equity attributable to shareholders is projected at 2,185.76 million yuan, a slight increase of 0.24%[4] Performance Drivers - The company attributes the improved performance to the growth in demand for lithium battery electrolyte additives and a decrease in raw material costs for its pharmaceutical products[6]